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ABSTRACT
Objectives: Adding, omitting or changing prespecified
outcomes can result in bias because it increases the
potential for unacknowledged or post hoc revisions of
the planned analyses. Journals have adopted initiatives
such as requiring the prospective registration of trials
and the submission of study protocols to promote the
transparency of reporting in clinical trials. The main
objective of this feasibility study was to document the
frequency and types of outcome discrepancy between
prespecified outcomes in the protocol and reported
outcomes in trials submitted to The BMJ.
Methods: A review of all 3156 articles submitted to
The BMJ between 1 September 2013 and 30 June
2014. Trial registry entries, protocols and trial reports
of randomised controlled trials published by The BMJ
and a random sample of those rejected were reviewed.
Editorial, peer reviewer comments and author
responses were also examined to ascertain any
reasons for discrepancies.
Results: In the study period, The BMJ received 311 trial
manuscripts, 21 of which were subsequently published
by the journal. In trials published by The BMJ, 27% (89/
333) of the prespecified outcomes in the protocol were
not reported in the submitted paper and 11% (31/275) of
reported outcomes were not prespecified. In the sample
of 21 trials rejected by The BMJ, 19% (63/335) of
prespecified outcomes went unreported and 14% (45/
317) of reported outcomes were not prespecified. None
of the reasons provided by published authors were
suggestive of outcome reporting bias as the reasons
were unrelated to the results.
Conclusions: Mandating the prospective registration of
a trial and requesting that a protocol be uploaded when
submitting a trial article to a journal has the potential to
promote transparency and safeguard the evidence base
against outcome reporting biases as a result of outcome
discrepancies. Further guidance is needed with regard to
documenting reasons for outcome discrepancies.
INTRODUCTION
Selective outcome reporting occurs when a
subset of the originally recorded outcome
variables in a trial are selectively reported in
a publication based on their results. When
outcome reporting is informed by the statis-
tical signiﬁcance and/or effect size (eg, out-
comes where the results are not statistically
signiﬁcant are not reported or reported only
as p>0.05), we refer to this as outcome
reporting bias.1 This form of bias has been
identiﬁed as a threat to evidence-based
healthcare because clinical trial outcomes
with statistically signiﬁcant results are more
likely to be published.2 As a safeguard
against this form of bias, current CONSORT
(Consolidating Standards of Reporting
Trials) guidance recommends that com-
pletely deﬁned primary and secondary
outcome measures should be prespeciﬁed
and any changes to trial outcomes after the
trial starts should be documented with
reasons (CONSORT, items 6a and 6b); and
the results for each outcome should be
reported for each group, and the estimated
effect size and its precision (item 17a)
should also be reported.3 Despite this guid-
ance, empirical research has shown that stat-
istically signiﬁcant outcomes were more likely
to be fully reported (where a fully reported
outcome was one with sufﬁcient data for
inclusion in a systematic review meta-analysis)
Strengths and limitations of this study
▪ The BMJ manuscript tracking system was used
to gain access to all study protocols which are
often unavailable.
▪ The study assumed that unpublished protocols
submitted to The BMJ were final versions.
▪ The study only described reasons for outcome
discrepancies that were documented by the trial
authors or questioned during peer review.
▪ The results were limited to trials submitted to
The BMJ which may not be representative of all
trials.
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compared with non-signiﬁcant outcomes (range of ORs
2.2–4.7).4 When comparing trial publications with proto-
cols, it was found that 40–62% of studies had at least
one primary outcome that was changed, introduced or
omitted.4 Previous qualitative research in this ﬁeld has
found that the prevalence of incomplete outcome
reporting is high and researchers were generally
unaware of the implications of not reporting all out-
comes and protocol changes.5
Some journals have adopted policies such as the
International Committee of Medical Journal Editors
(ICMJE) recommendations to deter trial authors from
selectively reporting outcomes. For example, all The BMJ
follow the recommendation that any clinical trial which
started after 1 July 2005 will only be considered for publi-
cation if the trial was prospectively registered before the
recruitment of any participants (http://journals.bmj.
com/site/authors/editorial-policies.xhtml#clinicaltrial).
The BMJ will also not consider a report of a clinical trial
unless the protocol is also submitted to inform the peer
review process.
The aim of this feasibility study was to gain an under-
standing of the practicalities of comparing prespeciﬁed
outcomes from the trial protocol and reported outcomes
in the initial manuscript submission during the peer
review process in order to inform a larger future study.
We take a cohort of trial reports submitted to The BMJ
where half of the trials were recently accepted for publi-
cation by The BMJ and half were rejected. The main
objective of the study was to document the frequency and
types of outcome discrepancy between prespeciﬁed out-
comes in the protocol and reported outcomes in the sub-
mitted paper. A secondary objective was to review
whether these discrepancies were discussed by authors in
the trial registry or manuscript, or in the case where the
manuscripts underwent external peer review, during cor-
respondence with editors and peer reviewers.
METHODS
Identification of trials
After signing a conﬁdentiality agreement, we searched
The BMJ’s manuscript tracking system to identify all
reports of randomised controlled trials (RCTs) submit-
ted to the journal between 1 September 2013 and 30
June 2014. Articles are archived after a 12-month period
in the system, and therefore this 10-month period was
chosen in order to avoid the loss of any articles between
the screening and assessment stage. We included only
articles that assessed the efﬁcacy or effectiveness of a
medical intervention and were submitted as the primary
study publication as indicated by the trial author. If it
was unclear as to whether the article was a primary pub-
lication, two experienced members of the study team
( JK and PW) made a judgement via discussion.
Secondary trial papers including cost-effectiveness ana-
lyses were excluded, since such articles are unlikely to
report on all prespeciﬁed outcomes.
The study followed a nested case–control study design.
From the cohort of all RCT submissions to The BMJ
meeting the inclusion criteria, cases were deﬁned to be
all trials that were submitted in the chosen period and
subsequently published by The BMJ. Controls consisted
of a random sample (of equal size to the number that
were published) of submitted and subsequently rejected
articles. All rejected articles had equal chance of selec-
tion irrespective of the stage in which they were rejected,
that is, following initial screening, following external
peer review or after an appeal. If a rejected article did
not have a submitted protocol, then the next rejected
article in the random sequence was selected until
enough controls were selected.
Trial documentation for assessment
For each submission, we downloaded the trial registry
entry and the following documents from The BMJ’s
manuscript tracking system: study protocol, ﬁrst submis-
sion, any online supplementary material, editor and
peer review comments with author responses, and ﬁnal
published article available on ScholarOne. Trial registry
entries were identiﬁed from the ‘trial registration’ name
and number reported as a required abstract item for
RCT manuscripts submitted to The BMJ.
Assessment of trials and data extraction
Using the detail from the submitted articles, we
recorded trial characteristics relating to the design,
conduct and size of the trial. For trials rejected by The
BMJ, we recorded the main reason why the article was
rejected since not all rejections are based on methodo-
logical reasons, for example, an article maybe rejected
because the research question lacks novelty, relevance or
importance. We also recorded whether or not the trial
was prospectively/retrospectively registered according to
the ICMJE deﬁnition,6 and whether or not the protocol
submitted to the journal was published. In addition, we
recorded any outcomes-related changes with reasons
that were documented in either of the historic changes
and amendments section of the trial registry entries or
the trial articles.
Outcome definitions used in this study
We deﬁned outcomes of interest as domains. An
outcome-speciﬁc measurement is the metric or tool used to
support the measurement of the domain. These deﬁni-
tions are coherent with those used in other studies.7 8
Some speciﬁc measurements have multiple subscales, for
example, the Short Form-36 (SF-36) for measuring
general health has eight health subscales and two
summary scores (the physical and mental component
summary scores). We treated each subscale as a separate
outcome only if it was the triallists’ intention to analyse
each subscale separately.
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Outcome comparisons and assessment
Comparison of outcomes listed in the trial registry, the
trial protocol, the initial article submission and the ﬁnal
published article (if available) was undertaken inde-
pendently by two researchers ( JW and JK or JW and
KD) to identify any similarities or discrepancies in
outcome speciﬁcation between the source documents.
For each trial, a matrix listing the outcome domains,
and speciﬁc measurements was constructed showing
whether the outcome was mentioned in each of the four
possible source documents. If only an outcome domain
was prespeciﬁed without reference to individual sub-
scales, then this was not classed as a discrepancy if the
individual outcomes were reported. For example, in
rheumatology, if the disease activity index was prespeci-
ﬁed but the individual components of the index were
reported, but not prespeciﬁed (tender joint count,
swollen joint count, patient global health and acute
phase reactant), then this was not classiﬁed as a discrep-
ancy. Similarly, a discrepancy was not declared if the spe-
ciﬁc measurement instruments used to measure
outcomes were not prespeciﬁed. For example, if quality
of life was listed as a prespeciﬁed outcome and the
report used the EQ-5D to measure quality of life then
this was not considered a discrepancy.
Any discrepancies between the information extracted
by the two reviewers were resolved through discussion.
As an additional quality control check, one author ( JK)
checked all comparisons.
Data analysis and presentation of results
Trials were analysed and presented in accordance to
whether or not they were accepted or rejected for publi-
cation by The BMJ. Inconsistencies between prespeciﬁed
outcomes (those listed in the protocol) and those
reported in the initial trial report submission were docu-
mented. As a supplementary analysis, we also considered
prespeciﬁed outcomes to be those listed in the trial
registry. Speciﬁc discrepancy types comprised new out-
comes introduced into the trial report that were not pre-
speciﬁed and prespeciﬁed outcomes that were not
mentioned in the trial report. We also noted any
changes in the importance of outcomes (eg, upgrading
and downgrading prespeciﬁed outcomes to primary and
secondary outcomes, respectively) and changes in meas-
urement tools used.
For articles published by The BMJ, a review of the edi-
torial, peer review and authors’ responses was also
undertaken. We describe how often outcomes discrepan-
cies were picked up during peer review, by whom and
any reasons that were provided by the authors for the
discrepancy. Outcomes that were reported in the ﬁnal
published manuscript were compared with those
reported in the initial submission and any changes in
the discrepancy rates between the protocol and initial
submission and ﬁnal published article reported. Any
reduction in the discrepancy rate between the protocol
and the ﬁnal publication was seen as a crude measure of
the impact of the peer review process when compared
with the initial manuscript submission.
RESULTS
Between 1 September 2013 and 30 June 2014, 3156
research articles were submitted to The BMJ but only
10% (311/3156) of these were RCT related (ﬁgure 1).
Thirty-six RCTs were excluded for reasons described in
ﬁgure 1. Of the remaining 275 RCTs, 21 (8%) were
accepted for publication by The BMJ and the remaining
254 were rejected. As a requirement of publication, all
accepted RCTs had an available protocol within the
manuscript tracking system but authors of more than a
half of the rejected RCTs (55%; 139/254) did not
submit a protocol during the initial submission
(ﬁgure 1).
Characteristics of the 21 accepted trials and 21 ran-
domly selected trials from the 115 rejected submissions
with an available protocol are shown in table 1. No trial
was exclusively funded by industry and all trials were
registered. Dates of trial registrations for accepted RCTs
ranged from 2006 to 2012, for accepted protocols
ranged from 1998 to 2013. Dates of trial registrations for
rejected RCTs ranged from 2005 to 2012, for rejected
protocols ranged from 2004 to 2013. A higher propor-
tion of trials that were rejected by The BMJ were retro-
spectively registered and there was a tendency for more
trials that were accepted by The BMJ to have a published
protocol. The median number of outcomes mentioned
in the source documents for trials accepted by The BMJ
was 15 (range 4–42) and the median for those rejected
by The BMJ was 19 (range 3–35). Sixteen of the rejected
articles were rejected by the editor following initial
screening, four were rejected after external peer review
and one was rejected following an appeal. The decision
made by the editor to reject the article was retrospective
registration for 5 of the 21 rejected trials. Other reasons
for rejection included preliminary study/low priority for
journal (6), not suitable for publication in The BMJ (5),
article would be more suitable in a specialist journal (3),
underpowered study (1) and premature termination of
trial (1). As of April 2015, 12 of the 21 articles rejected
by The BMJ have been identiﬁed as published elsewhere
(table 2).
Outcome discrepancies—protocol to initial manuscript
submission
In trials published by The BMJ, over a quarter of the pre-
speciﬁed outcomes (27% (89/333)) in the protocol were
not reported in the initial manuscript submission; 19%
(63/335) in those trials that were rejected (table 2).
Eleven per cent (31/275) of outcomes reported in the
initial manuscript submission that were published by The
BMJ were not prespeciﬁed compared with 14% (45/317)
in those trials that were rejected (table 2). There were no
discrepancies between prespeciﬁed and reported
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outcomes in 19% (4/21) of trials accepted by The BMJ
and 10% (2 of the 21 trials) rejected by The BMJ.
We found three instances from three separate trials
(all subsequently accepted by The BMJ) where a prespe-
ciﬁed primary outcome was downgraded to a secondary
outcome in the submitted report (table 2). None of the
trial authors speciﬁed a reason for this change, although
one author did amend the trial registry entry accord-
ingly. Prespeciﬁed secondary outcomes were not
upgraded to primary outcomes in any of the submitted
trial reports.
Outcome discrepancies—trial registry to initial manuscript
submission
Online supplementary table S1 provides the results
where the trial registry was used to deﬁne the prespeci-
ﬁed list of outcomes. In comparison to using the proto-
col to deﬁne the list of prespeciﬁed outcomes, there was
a marked increase in the number of reported outcomes
that were not prespeciﬁed; 32% (87/275) for the trials
accepted by The BMJ and 28% (90/317) for the trials
rejected by The BMJ.
Reasons for discrepancies
Three rejected trial reports noted changes to outcomes
in either the trial registry or protocol but did not docu-
ment a reason for the change.
Editorial impact on discrepancies (trials accepted for
publication by The BMJ)
In the 21 trials accepted by The BMJ, the editorial and
peer review process raised awareness about outcome dis-
crepancies in 82% (14/17) of the trials where there
were outcome discrepancies. Editors asked authors of 10
trials to make sure all registered outcomes were reported
in the trial manuscript and to document any reasons for
changes. The percentage of prespeciﬁed outcomes that
went unreported following peer review reduces from
27% to 21% (71/333) when substituting the initial
manuscript submission for the ﬁnal published article in
the assessment, but the percentage of outcomes that
were reported but not prespeciﬁed remained largely
unchanged (11%, 32/294; see online supplementary
table S2). Editors did, however, request that reported
outcomes that were not prespeciﬁed were labelled as
Figure 1 Flow diagram of
research articles submitted to The
BMJ (1 September 2013 to 30
June 2014).
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‘post hoc’ (ﬁve trials). In responding to peer reviewer
comments, two authors suggested that qualitative and
subjective outcome measures were to be reported else-
where, and in one trial there was clear evidence that the
additional data had been published elsewhere. Authors
also reported space limitations (despite the fact that The
BMJ has no word limit for research), outcomes still
being analysed and errors with updating the trial registry
entry in their communications with editors as reasons
for outcome discrepancies identiﬁed during the peer
review process.
DISCUSSION
Researchers have a moral responsibility to report trial
ﬁndings completely and transparently.9 Mandating the
prospective registration of a trial and requesting that a
protocol be uploaded when submitting a trial article to a
journal have the potential to promote transparency and
reduce the incidence of outcome reporting biases as a
result of outcome discrepancies. Despite these require-
ments, the principal ﬁndings from this study showed
that, at The BMJ where these are mandated, over a
quarter of prespeciﬁed outcomes from trials that were
published by The BMJ may still go unreported in submit-
ted manuscripts reporting the primary trial results, while
just over 10% of outcomes were newly introduced. For
articles accepted by The BMJ, a review of editor, peer
reviewer and author responses revealed that reasons for
identiﬁed discrepancies given by trial investigators were
not considered to indicate bias, since the reason for the
discrepancies were unrelated to the results. There was
evidence that The BMJ peer review process reduces the
amount of unreported outcomes with fewer discrepan-
cies found between the protocol and the published trial
report than the initial submission. On a number of occa-
sions, editors also requested that reported outcomes that
were not prespeciﬁed were clearly labelled as post hoc
outcomes.
Comparison with other studies
Two empirical studies conducted by Chan and collea-
gues compared the protocol and the ﬁnal publication
with respect to the primary outcome and concluded that
40–62% of trials had major discrepancies between the
primary outcomes speciﬁed in the protocols and those
deﬁned in the published article.10 11 Four empirical
studies have found that between 13% and 31% of
primary outcomes speciﬁed in the protocol were
omitted in the publication, and between 10% and 18%
of reports introduced and outcome in the publication
that was not speciﬁed in the protocol.10–13 In one previ-
ous qualitative study, interviews were undertaken with
trial investigators to discuss any discrepancies found
between trial protocols and subsequent publications.5
This interview study found that in almost all trials (15/
16, 94%) in which prespeciﬁed outcomes had been ana-
lysed at the time of primary publication but not
Table 1 Characteristics of randomised controlled trials
included in the study
Characteristic
Accepted
by The
BMJ
n (%)
Rejected
by The
BMJ
n (%)
Trial design
Parallel 16 (76) 17 (81)
Cluster 4 (19) 3 (14)
Cross-over 0 (0) 1 (5)
Factorial 1 (5) 0 (0)
Multicentre/single centre
Multicentre 18 (86) 15 (71)
Single centre 3 (14) 6 (29)
Trial sample size
<100 1 (5) 4 (19)
100–999 14 (67) 13 (62)
>1000 6 (29) 4 (19)
Duration of trial (follow-up)
<12 months 8 (38) 10 (48)
12 to 24 months 12 (57) 9 (43)
>24 months 1 (5) 1 (5)
Unclear 0 (0) 1 (5)
Location of lead investigator
UK 10 (48) 6 (29)
Rest of Europe 6 (29) 5 (24)
North America 0 (0) 1 (5)
Rest of World 5 (24) 9 (43)
Source of funding
Commercial 0 (0) 0 (0)
Non-commercial 15 (71) 18 (86)
Both 5 (24) 3 (14)
Not stated 1 (5) 0 (0)
Trial registration
Yes 21 (100) 21 (100)
No 0 (0) 0 (0)
Where was the trial registered
Clinical trials.gov 2 (10) 6 (29)
ISRCTN Register 16 (76) 9 (43)
Australian/New Zealand CTR 1 (5) 5 (24)
Dutch Trial Register 2 (10) 0 (0)
UMIN CTR 0 (0) 1 (5)
Prospective/retrospective registered
Prospective 19 (91) 10 (48)
Retrospective 1* (5) 10 (48)
Unclear† 1 (5) 1 (5)
Published protocol
Yes 14 (67) 11 (52)
No 7 (33) 10 (48)
Where was the protocol published: (n=14 accepted, n=11
rejected)
BMC series 13 (93) 10 (91)
Other 1‡ (7) 1§ (9)
*Study started March 1999, prior to ICMJE trial registration
recommendation.
†Exact date first participant recruited into trial not provided.
‡Published in Contemporary Clinical Trials.
§Published in Journal of Foot and Ankle Research.
BMC, BioMed Central; CTR, Clinical Trial Registry; ICMJE,
International Committee of Medical Journal Editors; ISRCTN,
International Standard Randomised Controlled Trials Number;
UMIN, University Hospital Medical Information Network.
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Table 2 Outcome discrepancies between prespecified (protocol) and reported outcomes (initial submission) from trials submitted to The BMJ
Trials accepted by The BMJ (n=21 trials) Trials rejected by The BMJ (n=21 trials)
Discrepancy type Discrepancy type
Article
ID
Registration
type
Total
number of
outcomes
prespecified*
Prespecified
outcomes not
reported†
New
outcomes
introduced‡
Total
number of
outcomes
reported§
Change in
level of
importance
of an
outcome¶
Article
ID
Registration
type
Total
number of
outcomes
prespecified*
Prespecified
outcomes
not
reported†
New
outcomes
introduced‡
Total
number of
outcomes
reported§
Change in
level of
importance
of an
outcome¶
A1 Prospective 15 2 0 13 0 R1 Prospective 4 0 2 6 0
A3 Prospective 11 8 1 4 0 R4 Prospective 20 4 1 17 0
A4 Prospective 21 2 6 25 (−1) R6 Prospective 15 4 0 11 0
A5 Prospective 23 16 2 9 0 R8 Prospective 20 2 2 20 0
A6 Prospective 12 5 4 11 (−1) R10 Prospective 22 0 2 24 0
A7 Prospective 10 0 0 10 0 R11 Prospective 30 19 3 14 0
A8 Prospective 14 0 2 16 0 R16 Prospective 5 1 0 4 0
A9 Prospective 25 8 2 19 0 R19 Prospective 11 5 11 17 0
A10 Prospective 22 3 5 24 0 R20 Prospective 15 0 1 16 0
A11 Prospective 5 2 2 5 0 R21 Prospective 3 0 0 3 0
A12 Prospective 10 1 0 9 0 R2 Retrospective 20 1 0 19 0
A13 Prospective 3 0 0 3 0 R3 Retrospective 22 0 0 22 0
A14 Prospective 5 0 0 5 0 R7 Retrospective 29 4 6 31 0
A15 Prospective 29 3 0 26 0 R9 Retrospective 15 7 0 8 0
A16 Prospective 8 0 0 8 0 R12 Retrospective 12 0 8 20 0
A17 Prospective 22 0 2 24 0 R13 Retrospective 16 8 0 8 0
A19 Prospective 13 2 0 11 0 R14 Retrospective 6 0 2 8 0
A20 Prospective 41 24 1 18 (−1) R15 Retrospective 18 1 0 17 0
A21 Prospective 21 1 0 20 0 R17 Retrospective 18 2 7 23 0
A18 Retrospective 7 6 2 3 0 R18 Retrospective 15 2 0 13 0
A2 Unclear 16 6 2 12 0 R5 Unclear 19 3 0 16 0
Total 333 89 31 275 (−3) Total 335 63 45 317 0
Prespecified but not reported (accept BMJ): 27% (89/333)
Reported but not prespecified (accept BMJ): 11% (31/275)
Prespecified but not reported (reject BMJ): 19% (63/335)
Reported but not prespecified (reject BMJ): 14% (45/317)
*Prespecified: total number of outcomes listed in trial protocol.
†Outcomes mentioned in protocol but not reported in the initial article submission.
‡Outcomes not prespecified in protocol but reported in the initial article submission.
§Reported: total number of outcomes reported in initial submission. If only an outcome domain was specified in the protocol, all outcomes reported within this domain were counted.
¶Minus (−), number of prespecified protocol outcomes downgraded from primary to secondary outcomes in initial trial report submission; Plus (+), number of prespecified or protocol
outcomes upgraded from secondary to primary in the initial trial report submission.
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reported, this under-reporting resulted in bias. In nearly
a quarter (4/17, 24%) of trials in which prespeciﬁed
outcomes had been collected but not analysed, the dir-
ection of the main ﬁndings inﬂuenced the investigators’
decision to not analyse the remaining data collected.
Strengths and limitations
The strength of our study rests in the use of The BMJ’s
tracking system to gain access to the study protocols for
each comparison. However, we did make the assumption
that unpublished protocols submitted to The BMJ were
ﬁnalised and no further undocumented changes were
made after any outcome data were analysed. We also
deﬁned prespeciﬁed outcomes to be those listed in the
protocol since many of the rejected trials were retro-
spectively registered and therefore may not be truly ‘pre-
speciﬁed’ outcomes, making any comparison between
rejected and accepted trials unfair. Nevertheless, we
acknowledge that at this time, there are no reliable,
practical processes available to identify version numbers
and time stamps for unpublished protocols.
A further limitation of our work is that we were only
able to document reasons for outcome discrepancies
that were either documented by the trial author in the
source documentation or questioned during peer
review. Our research uncovered many other outcome
discrepancies for which the reasons are unknown. Many
of these unknown reasons could be the result of
outcome reporting bias. We should also be aware that
over half of the authors of rejected trials that were not
considered for full assessment in this study did not
upload a protocol at submission. Without a protocol, a
full assessment would not have been possible but also we
have assumed implicitly that those rejected trials with an
available protocol were not different in terms of selective
reporting than those that did not submit a protocol.
Furthermore, our results apply only to reports of trials
submitted to The BMJ, which may not be representative
of all trials; for example, no industry trials are included
in the sample. Selective outcome reporting and discrep-
ancies in outcome measures has previously been identi-
ﬁed in industry-funded trials where the study protocol
were supplied through litigation.14
Conclusions and policy implications
There are familiar lessons from this study for triallists,
journal editors and peer reviewers. Triallists must write
sufﬁciently detailed protocols, clearly identify any amend-
ments and new versions, and adhere to them to minimise
the scope for outcome reporting bias. The trial protocols
supplied to The BMJ were highly variable in terms of
quality, clarity and depth. For this reason, The BMJ
research editors always use the publicly-registered infor-
mation about the trial as the main source of prespeciﬁed
outcomes. When reporting ﬁndings, triallists should
ensure that trial registry entries correspond to the proto-
col. They should describe clearly in trial reports out-
comes that were measured, analysed and compared, and
report and explain deviations from or additions to
planned outcomes. We found that none of the trial
authors explained the outcome changes in the trial regis-
try entries and submitted reports. We also found that
many trial registry entries specify only outcome domains
without specifying individual-speciﬁc measurement tools
and subscales which are to be used and the time points in
which outcomes are to be measured. Journal editors and
peer reviewers need to be able to identify all outcome dis-
crepancies during peer review and should compare out-
comes prespeciﬁed (both primary and secondary
outcomes) in the trial registry and protocol to those
reported in the submitted report. Authors should be
asked to make a comment on the reasons for all outcome
discrepancies following peer review and journal editors
should recommend that triallists upload these reasons
into the trial registry entry as well as being included in
the trial report. Authors should also ensure that any pre-
speciﬁed outcomes not reported in the main manuscript
are easily accessible if not published elsewhere.
In addition to journal editors, trial steering committees
for individual trials can also perform a role in providing
trial authors with guidance regarding outcome speciﬁca-
tion, monitoring changes in outcomes and measures,
and observing good practice in line with reporting stan-
dards. The SPIRIT guideline (Standard Protocol Items:
Recommendations for Interventional Trials) is a valuable
resource for triallists at the development stage of a trial
protocol, and we encourage the use of such guidelines to
aid transparency of outcome selection and reporting.15
Future work
Understanding the reasons for outcome discrepancies is
important in order to identify what kind of mechanisms
drive outcome reporting bias and also to provide guid-
ance on how to minimise it. A larger study looking at
outcome discrepancies involving more journals needs to
be undertaken in order to gain insight into different
journal policies using the methods outlined in this feasi-
bility study. Owing to the problems with recall bias in
the previous interview study,5 interviews with triallists
during the peer review process need to be undertaken
to identify the reasons for all outcome discrepancies.
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